"We are pleased to be working with Isis, a leader in the discovery and development of RNA-based therapeutics," stated Pratik Shah, Ph.D., partner at Thomas, McNerney & Partners, which structured and led the licensing and financing transactions for Altair. "Asthma continues to be an area of unmet medical need and we believe ISIS 369645 has the potential to provide significant benefit to patients. There have been a number of recent clinical successes and validating corporate partnerships that make this space exciting."
"A key component of our business strategy is to exploit the broad applicability of our antisense technology platform and our intellectual property position to add to our pipeline of promising antisense drugs that target a broad range of diseases," said B. Lynne Parshall, Executive Vice President and CFO of Isis. "To best accomplish this, we have created and partnered with numerous emerging biotech companies focused on exploiting antisense technology toward new biological areas or particular diseases, providing them with access to our technology, intellectual property or licenses to certain of our drugs. Altair is now joining the ranks of these partners, which include Alnylam Pharmaceuticals, OncoGenex Technologies, Regulus Therapeutics, ATL, iCo Therapeutics and others. We believe that each of these partners is a highly dedicated, innovative company through which we are aggressively furthering the development of antisense drugs, expanding the breadth of our product pipeline, and creating value, while staying focused on our internal drug discovery and development activities and core technology expansion."
About Altair Therapeutics
Altair was founded by Thomas, McNerney & Partners and is building a
dedicated team, combining antisense drug discovery expertise with
respiratory drug development expertise, to focus solely on the development
and commercialization of
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved